Table 1.
Clinical characteristics of mCRC patients treated with anti-BRAF/EGFR combinatory regimens in 2nd or third lines in CGDB by RNF43 and MSI status.
| Study population (n = 49) | RNF43 mut, MSS (n = 12) | RNF43 wt, MSS (n = 31) | RNF43 mut, MSI-H (n = 5) | |
|---|---|---|---|---|
| Age (years) | ||||
| <70 | 46 (93.9%) | 11 (91.7%) | 29 (93.5%) | 5 (100.0%) |
| ≥70 | 3 (6.1%) | 1 (8.3%) | 2 (6.5%) | 0 |
| Gender | ||||
| Female | 27 (55.1%) | 8 (66.7%) | 13 (41.9%) | 5 (100.0%) |
| Male | 22 (44.9%) | 4 (33.3%) | 18 (58.1%) | 0 |
| ECOG | ||||
| 0 | 20 (42.6%) | 6 (50.0%) | 13 (44.8%) | 1 (20.0%) |
| 1-3 | 27 (47.4%) | 6 (50.0%) | 16 (55.2%) | 4 (80.0%) |
| N-miss | 2 | 0 | 2 | 0 |
| Primary tumor location | ||||
| Left colon/rectum | 15 (30.6%) | 3 (25.0%) | 12 (38.7%) | 0 |
| Right colon | 22 (44.9%) | 7 (58.3%) | 12 (38.7%) | 2 (40.0%) |
| NOS | 12 (24.5%) | 2 (16.7%) | 7 (22.6%) | 3 (60.0%) |
| Treatment line | ||||
| Second | 34 (69.4%) | 8 (66.7%) | 21 (67.7%) | 4 (80.0%) |
| Third | 15 (30.6%) | 4 (33.3%) | 10 (32.3%) | 1 (20.0%) |
| Combinatory treatment | ||||
| Doublet | 37 (75.5%) | 9 (75.0%) | 22 (71.0%) | 5 (100.0%) |
| Triplet | 12 (24.5%) | 3 (25.0%) | 9 (29.0%) | 0 |
| Received ICI | ||||
| Yes | 7 (14.3%) | 1 (8.3%) | 2 (6.5%) | 3 (60.0%) |
| No | 42 (85.7%) | 11 (91.7%) | 29 (93.5%) | 2 (40.0%) |
| Mutation in other genes of the Wnt pathway | ||||
| AMER1 | 3 (6.1%) | 0 | 1 (3.2%) | 2 (6.4%) |
| APC | 15 (30.6%) | 0 | 15 (48.4%) | 0 |
| AXIN1 | 0 | 0 | 0 | 0 |
| CTNNB1 | 0 | 0 | 0 | 0 |
Abbreviations: CGDB: clinic-genomics database; Doublet: encorafenib with cetuximab or panitumumab; ECOG: Eastern Cooperative Oncology Group; ICI: immune checkpoint inhibitor; mCRC: metastatic colorectal cancer; MSI-H: microsatellite instability high; MSS: microsatellite stable; mut: mutation; NOS: not otherwise specified; Triplet: encorafenib with cetuximab or panitumumab ± binimetinib; wt: wild type.